Symbol="SABSW"
AssetType="Common Stock"
Name="SAB Biotherapeutics Inc"
Description="SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. The company is headquartered in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts."
CIK="1833214"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2100 EAST 54TH STREET NORTH, SIOUX FALLS, SD, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="None"
EBITDA="-26180640"
PERatio="0.291"
PEGRatio="None"
BookValue="0.484"
DividendPerShare="0"
DividendYield="0"
EPS="0.292"
RevenuePerShareTTM="0.28"
ProfitMargin="-2.135"
OperatingMarginTTM="-2.335"
ReturnOnAssetsTTM="-0.336"
ReturnOnEquityTTM="-0.825"
RevenueTTM="12682200"
GrossProfitTTM="0"
DilutedEPSTTM="0.292"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.951"
AnalystTargetPrice="None"
TrailingPE="0.291"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="-"
EVToRevenue="-"
EVToEBITDA="-"
Beta="1.334"
num_52WeekHigh="0.225"
num_52WeekLow="0.0275"
num_50DayMovingAverage="0"
num_200DayMovingAverage="0"
SharesOutstanding="0"
DividendDate="None"
ExDividendDate="None"
symbol="SABSW"
open="0.10"
high="0.12"
low="0.09"
price="0.09"
volume="60439.00"
latest_trading_day="2023-08-04"
previous_close="0.09"
change="0.00"
change_percent="0.0000%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="17"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="83"
Volume_recent_avg="20616"
Change_recent_avg="0.01"
Delta_recent_avg="0.02"
Variance_recent_avg="0.01"
Change_ratio_recent_avg="-2.0"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="83"
Aroon_momentum_negative="17"
image_negative_thumbnail_id_1="1142"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0175.jpeg"
image_negative_thumbnail_id_2="1163"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0197.jpeg"
image_neutral_thumbnail_id_1="523"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0076.jpeg"
image_neutral_thumbnail_id_2="524"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_positive_thumbnail_id_1="1006"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0168.jpeg"
image_positive_thumbnail_id_2="964"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0126.jpeg"
image_professor_thumbnail_id_1="1169"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
